Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
Did you mean: (antiarrhythmic)?
221,129 results
  • [Cancer cell-specific functional relation between Na+,K+-ATPase and volume-regulated anion channel]. [Journal Article]
    Nihon Yakurigaku Zasshi 2019; 154(3):103-107Fujii T, Shimizu T, … Sakai H
  • Digitoxin and digoxin are plant-derived cardiac glycosides. They are Na+,K+-ATPase (sodium pump) inhibitors, and have been used clinically for treatment and prevention of heart failure and various tachycardia. On the other hand, some epidemiological studies showed that digoxin users have a lower cancer risk compared to the non-users, and that cancer patients who had been treated with digoxin face…
  • The Many Faces of Early Repolarization Syndrome:A Single Center Case-Series. [Journal Article]
    Heart Rhythm 2019Voskoboinik A, Hsia H, … Scheinman MM
  • CONCLUSIONS: ERS is a heterogeneous condition and may be associated with both atrial and ventricular arrhythmias, AV block, dynamic electrocardiographic changes and variable triggers. In addition to targeting PVC triggers, mapping and ablation of abnormal epicardial electrograms may be a potential future treatment strategy.
  • Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. [Review]
    Cochrane Database Syst Rev 2019; 9:CD005049Valembois L, Audureau E, … Lafuente-Lafuente C
  • CONCLUSIONS: There is high-certainty evidence of increased mortality associated with sotalol treatment, and low-certainty evidence suggesting increased mortality with quinidine, when used for maintaining sinus rhythm in people with atrial fibrillation. We found few data on mortality in people taking disopyramide, flecainide and propafenone, so it was not possible to make a reliable estimation of the mortality risk for these drugs. However, we did find moderate-certainty evidence of marked increases in proarrhythmia and adverse effects with flecainide.Overall, there is evidence showing that antiarrhythmic drugs increase adverse events, increase proarrhythmic events and some antiarrhythmics may increase mortality. Conversely, although they reduce recurrences of atrial fibrillation, there is no evidence of any benefit on other clinical outcomes, compared with placebo or no treatment.
New Search Next